Benefits and risks of anthracyclines in early-stage breast cancer

Fernando Kude de Almeida¹, Frederico Soares Falcetta², Daniela Dornelles Rosa³

Affiliations

¹ Division of Oncology, Hospital Femina, Porto Alegre 90430, Brazil. Electronic address: fernandokude@gmail.com.
² Division of Clinical Pathology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
³ Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

PMID: 38555132
DOI: 10.1016/S0140-6736(23)02889-1

Comment

Benefits and risks of anthracyclines in early-stage breast cancer

Fernando Kude de Almeida et al. Lancet. 2024.

. 2024 Mar 30;403(10433):1239-1240.

doi: 10.1016/S0140-6736(23)02889-1.

Authors

Fernando Kude de Almeida¹, Frederico Soares Falcetta², Daniela Dornelles Rosa³

Affiliations

¹ Division of Oncology, Hospital Femina, Porto Alegre 90430, Brazil. Electronic address: fernandokude@gmail.com.
² Division of Clinical Pathology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
³ Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

PMID: 38555132
DOI: 10.1016/S0140-6736(23)02889-1

No abstract available

PubMed Disclaimer

Comment in

Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
Braybrooke J, Bradley R, Gray R, Hills R; Early Breast Cancer Trialists' Collaborative Group. Braybrooke J, et al. Lancet. 2024 Mar 30;403(10433):1240. doi: 10.1016/S0140-6736(23)02890-8. Lancet. 2024. PMID: 38555133 No abstract available.

Comment on

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Benefits and risks of anthracyclines in early-stage breast cancer

Affiliations

Benefits and risks of anthracyclines in early-stage breast cancer

Authors

Affiliations

Comment in

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical